tetano
Editor, Senior Moderator
Vaccine
. 2023 Jan 6;S0264-410X(22)01602-4.
doi: 10.1016/j.vaccine.2022.12.067. Online ahead of print.
Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice
Yuyeon Jang[SUP] 1 [/SUP], Hansam Cho[SUP] 2 [/SUP], Jungmin Chun[SUP] 3 [/SUP], Kihoon Park[SUP] 2 [/SUP], Aleksandra Nowakowska[SUP] 4 [/SUP], Jinha Kim[SUP] 4 [/SUP], Hyeondong Lee[SUP] 4 [/SUP], Chanyeong Lee[SUP] 4 [/SUP], Yejo Han[SUP] 2 [/SUP], Hee-Jung Lee[SUP] 4 [/SUP], Ha-Youn Shin[SUP] 4 [/SUP], Young Bong Kim[SUP] 5 [/SUP]
Affiliations
Abstract
After severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) made the world tremble with a global pandemic, SARS-CoV2 vaccines were developed. However, due to the coronavirus's intrinsic nature, new variants emerged, such as Delta and Omicron, refractory to the vaccines derived using the original Wuhan strain. We developed an HERV-enveloped recombinant baculoviral DNA vaccine against SARS-CoV2 (AcHERV-COVID19S). A non-replicating recombinant baculovirus that delivers the SARS-CoV2 spike gene showed a protective effect against the homologous challenge in a K18-hACE2 Tg mice model; however, it offered only a 50 % survival rate against the SARS-CoV2 Delta variant. Therefore, we further developed the AcHERV-COVID19 Delta vaccine (AcHERV-COVID19D). The AcHERV-COVID19D induced higher neutralizing antibodies against the Delta variant than the prototype or Omicron variant. On the other hand, cellular immunity was similarly high for all three SARS-CoV2 viruses. Cross-protection experiments revealed that mice vaccinated with the AcHERV-COVID19D showed 100 % survival upon challenge with Delta and Omicron variants and 71.4 % survival against prototype SARS-CoV2. These results support the potential of the viral vector vaccine, AcHERV-COVID19D, in preventing the spread of coronavirus variants such as Omicron and SARS-CoV2 variants.
Keywords: AcHERV-COVID19 Delta vaccine; Baculoviral DNA vaccine; Cross protection; SARS-CoV-2; SARS-CoV-2 Variants; SARS-CoV-2 vaccine.
. 2023 Jan 6;S0264-410X(22)01602-4.
doi: 10.1016/j.vaccine.2022.12.067. Online ahead of print.
Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice
Yuyeon Jang[SUP] 1 [/SUP], Hansam Cho[SUP] 2 [/SUP], Jungmin Chun[SUP] 3 [/SUP], Kihoon Park[SUP] 2 [/SUP], Aleksandra Nowakowska[SUP] 4 [/SUP], Jinha Kim[SUP] 4 [/SUP], Hyeondong Lee[SUP] 4 [/SUP], Chanyeong Lee[SUP] 4 [/SUP], Yejo Han[SUP] 2 [/SUP], Hee-Jung Lee[SUP] 4 [/SUP], Ha-Youn Shin[SUP] 4 [/SUP], Young Bong Kim[SUP] 5 [/SUP]
Affiliations
- PMID: 36631359
- DOI: 10.1016/j.vaccine.2022.12.067
Abstract
After severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) made the world tremble with a global pandemic, SARS-CoV2 vaccines were developed. However, due to the coronavirus's intrinsic nature, new variants emerged, such as Delta and Omicron, refractory to the vaccines derived using the original Wuhan strain. We developed an HERV-enveloped recombinant baculoviral DNA vaccine against SARS-CoV2 (AcHERV-COVID19S). A non-replicating recombinant baculovirus that delivers the SARS-CoV2 spike gene showed a protective effect against the homologous challenge in a K18-hACE2 Tg mice model; however, it offered only a 50 % survival rate against the SARS-CoV2 Delta variant. Therefore, we further developed the AcHERV-COVID19 Delta vaccine (AcHERV-COVID19D). The AcHERV-COVID19D induced higher neutralizing antibodies against the Delta variant than the prototype or Omicron variant. On the other hand, cellular immunity was similarly high for all three SARS-CoV2 viruses. Cross-protection experiments revealed that mice vaccinated with the AcHERV-COVID19D showed 100 % survival upon challenge with Delta and Omicron variants and 71.4 % survival against prototype SARS-CoV2. These results support the potential of the viral vector vaccine, AcHERV-COVID19D, in preventing the spread of coronavirus variants such as Omicron and SARS-CoV2 variants.
Keywords: AcHERV-COVID19 Delta vaccine; Baculoviral DNA vaccine; Cross protection; SARS-CoV-2; SARS-CoV-2 Variants; SARS-CoV-2 vaccine.